BUY Dr. Lal Path Labs Ltd. — Kush Bohra
byKush BohraHorizon: NA (inferred Swing (≤2wk))1 Oct 2026via NDTV Profit (Live)
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
MACD above its signal line — bullish momentum
Technicals · macd·2 Oct · today
4 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days
Advisor consensus · adjacent horizon·1 Oct · yesterday
Dr. Lal PathLabs Ltd announces the completion of its acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, through its wholly-owned subsidiary DLPL Dubai. Sunshine Healthcare Limited is n
BSE · Company Update·26 Sept · 5d ago
Dr. Lal Path Labs Ltd. approved the acquisition of 70% stake in SN Genelab Private Limited for up to INR 168 Crores plus performance linked earn out. SN Genelab will become a subsidiary.
NSE · Outcome of Board Meeting·24 Sept · 1w ago
Dr. Lal PathLabs Ltd announced board approval for the acquisition of 70% stake in SN Genelab Private Limited for up to INR 168 Crores plus performance linked earn out. This acquisition aims to strengt
BSE · Company Update·24 Sept · 1w ago
Nothing found in this tip’s window yet.
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.